AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [Form 4] Keros Therapeutics, Inc. Insider Trading Activity

[Form 4] Keros Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

ADAR1 Capital Management LLC and related entities reported significant trading activity in Keros Therapeutics (KROS) securities on June 20, 2025. The transactions involved both direct stock sales and put option exercises:

  • ADAR1 Partners LP disposed of 1,500 shares of common stock: - 100 shares at $60 per share - 1,400 shares at $70 per share
  • Spearhead Insurance Solutions IDF LLC disposed of 200 shares at $70 per share
  • Related put options were exercised, corresponding to the stock dispositions: - One $60 strike put option for 100 shares - Sixteen $70 strike put options for 1,600 shares total

Following these transactions, ADAR1 Partners LP maintains beneficial ownership of 4,391,237 shares, while Spearhead Insurance Solutions holds 743,358 shares. All reporting persons are considered 10% owners of Keros Therapeutics, with Daniel Schneeberger serving as the manager of the related entities.

ADAR1 Capital Management LLC e le entit脿 correlate hanno segnalato un'attivit脿 di trading significativa sulle azioni di Keros Therapeutics (KROS) il 20 giugno 2025. Le operazioni hanno riguardato sia vendite dirette di azioni ordinarie sia l'esercizio di opzioni put:

  • ADAR1 Partners LP ha ceduto 1.500 azioni ordinarie: - 100 azioni a 60 dollari ciascuna - 1.400 azioni a 70 dollari ciascuna
  • Spearhead Insurance Solutions IDF LLC ha ceduto 200 azioni a 70 dollari ciascuna
  • Sono state esercitate opzioni put correlate alle vendite azionarie: - Un'opzione put con prezzo di esercizio di 60 dollari per 100 azioni - Sedici opzioni put con prezzo di esercizio di 70 dollari per un totale di 1.600 azioni

Dopo queste transazioni, ADAR1 Partners LP detiene la propriet脿 effettiva di 4.391.237 azioni, mentre Spearhead Insurance Solutions possiede 743.358 azioni. Tutti i soggetti segnalanti sono considerati possessori del 10% di Keros Therapeutics, con Daniel Schneeberger come gestore delle entit脿 correlate.

ADAR1 Capital Management LLC y entidades relacionadas reportaron una actividad significativa de negociaci贸n en valores de Keros Therapeutics (KROS) el 20 de junio de 2025. Las transacciones incluyeron tanto ventas directas de acciones comunes como el ejercicio de opciones put:

  • ADAR1 Partners LP dispuso de 1,500 acciones comunes: - 100 acciones a 60 d贸lares por acci贸n - 1,400 acciones a 70 d贸lares por acci贸n
  • Spearhead Insurance Solutions IDF LLC dispuso de 200 acciones a 70 d贸lares por acci贸n
  • Se ejercieron opciones put relacionadas con las disposiciones de acciones: - Una opci贸n put con precio de ejercicio de 60 d贸lares para 100 acciones - Diecis茅is opciones put con precio de ejercicio de 70 d贸lares para un total de 1,600 acciones

Tras estas transacciones, ADAR1 Partners LP mantiene la propiedad beneficiaria de 4,391,237 acciones, mientras que Spearhead Insurance Solutions posee 743,358 acciones. Todas las personas que reportan se consideran propietarios del 10% de Keros Therapeutics, con Daniel Schneeberger como administrador de las entidades relacionadas.

ADAR1 Capital Management LLC 氚� 甏�霠� 氩曥澑霌れ潃 2025雲� 6鞗� 20鞚� Keros Therapeutics(KROS) 歃濌秾鞐� 雽�頃� 欷戩殧頃� 瓯半灅 頇滊彊鞚� 氤搓碃頄堨姷雼堧嫟. 瓯半灅電� 歆侅爲 欤检嫕 毵る弰鞕� 頀嬱樀靺� 頄夓偓 氇憪毳� 韽暔頄堨姷雼堧嫟:

  • ADAR1 Partners LP電� 1,500欤�鞚� 氤错喌欤茧ゼ 觳橂秳頄堨姷雼堧嫟: - 欤茧嫻 60雼煬鞐� 100欤� - 欤茧嫻 70雼煬鞐� 1,400欤�
  • Spearhead Insurance Solutions IDF LLC電� 欤茧嫻 70雼煬鞐� 200欤�毳� 觳橂秳頄堨姷雼堧嫟
  • 欤检嫕 觳橂秳瓿� 甏�霠悳 頀嬱樀靺橃澊 頄夓偓霅橃棃鞀惦媹雼�: - 60雼煬 頄夓偓臧�鞚� 頀嬱樀靺� 1瓯�, 100欤� - 70雼煬 頄夓偓臧�鞚� 頀嬱樀靺� 16瓯�, 齑� 1,600欤�

鞚� 瓯半灅 鞚错泟 ADAR1 Partners LP電� 4,391,237欤�鞚� 鞁れ 靻岇湢甓岇潉 鞙犾頃橂┌, Spearhead Insurance Solutions電� 743,358欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氇摖 氤搓碃鞛愲姅 Keros Therapeutics鞚� 10% 靻岇湢鞛愲 臧勳＜霅橂┌, Daniel Schneeberger臧� 甏�霠� 氩曥澑鞚� 甏�毽瀽 鞐暊鞚� 毵￡碃 鞛堨姷雼堧嫟.

ADAR1 Capital Management LLC et les entit茅s associ茅es ont d茅clar茅 une activit茅 de trading importante sur les titres de Keros Therapeutics (KROS) le 20 juin 2025. Les transactions ont impliqu茅 脿 la fois des ventes directes d'actions ordinaires et l'exercice d'options de vente (put) :

  • ADAR1 Partners LP a c茅d茅 1 500 actions ordinaires : - 100 actions 脿 60 dollars chacune - 1 400 actions 脿 70 dollars chacune
  • Spearhead Insurance Solutions IDF LLC a c茅d茅 200 actions 脿 70 dollars chacune
  • Des options de vente li茅es ont 茅t茅 exerc茅es, correspondant aux cessions d'actions : - Une option put avec un prix d'exercice de 60 dollars pour 100 actions - Seize options put avec un prix d'exercice de 70 dollars pour un total de 1 600 actions

脌 la suite de ces transactions, ADAR1 Partners LP conserve la propri茅t茅 b茅n茅ficiaire de 4 391 237 actions, tandis que Spearhead Insurance Solutions d茅tient 743 358 actions. Toutes les personnes d茅clarantes sont consid茅r茅es comme propri茅taires de 10 % de Keros Therapeutics, Daniel Schneeberger 茅tant le gestionnaire des entit茅s associ茅es.

ADAR1 Capital Management LLC und verbundene Unternehmen meldeten am 20. Juni 2025 bedeutende Handelsaktivit盲ten mit Wertpapieren von Keros Therapeutics (KROS). Die Transaktionen umfassten sowohl direkte Aktienverk盲ufe als auch die Aus眉bung von Put-Optionen:

  • ADAR1 Partners LP ver盲u脽erte 1.500 Stammaktien: - 100 Aktien zu je 60 USD - 1.400 Aktien zu je 70 USD
  • Spearhead Insurance Solutions IDF LLC ver盲u脽erte 200 Aktien zu 70 USD pro Aktie
  • Zugeh枚rige Put-Optionen wurden ausge眉bt, entsprechend den Aktienver盲u脽erungen: - Eine Put-Option mit Aus眉bungspreis 60 USD f眉r 100 Aktien - Sechzehn Put-Optionen mit Aus眉bungspreis 70 USD f眉r insgesamt 1.600 Aktien

Nach diesen Transaktionen h盲lt ADAR1 Partners LP weiterhin den wirtschaftlichen Eigentum an 4.391.237 Aktien, w盲hrend Spearhead Insurance Solutions 743.358 Aktien besitzt. Alle meldenden Personen gelten als 10%-Eigent眉mer von Keros Therapeutics, wobei Daniel Schneeberger als Manager der verbundenen Unternehmen fungiert.

Positive
  • None.
Negative
  • 10% owner ADAR1 Capital Management disposed of a total of 1,700 shares through put option exercises at $60-70 per share, reducing their significant holdings

ADAR1 Capital Management LLC e le entit脿 correlate hanno segnalato un'attivit脿 di trading significativa sulle azioni di Keros Therapeutics (KROS) il 20 giugno 2025. Le operazioni hanno riguardato sia vendite dirette di azioni ordinarie sia l'esercizio di opzioni put:

  • ADAR1 Partners LP ha ceduto 1.500 azioni ordinarie: - 100 azioni a 60 dollari ciascuna - 1.400 azioni a 70 dollari ciascuna
  • Spearhead Insurance Solutions IDF LLC ha ceduto 200 azioni a 70 dollari ciascuna
  • Sono state esercitate opzioni put correlate alle vendite azionarie: - Un'opzione put con prezzo di esercizio di 60 dollari per 100 azioni - Sedici opzioni put con prezzo di esercizio di 70 dollari per un totale di 1.600 azioni

Dopo queste transazioni, ADAR1 Partners LP detiene la propriet脿 effettiva di 4.391.237 azioni, mentre Spearhead Insurance Solutions possiede 743.358 azioni. Tutti i soggetti segnalanti sono considerati possessori del 10% di Keros Therapeutics, con Daniel Schneeberger come gestore delle entit脿 correlate.

ADAR1 Capital Management LLC y entidades relacionadas reportaron una actividad significativa de negociaci贸n en valores de Keros Therapeutics (KROS) el 20 de junio de 2025. Las transacciones incluyeron tanto ventas directas de acciones comunes como el ejercicio de opciones put:

  • ADAR1 Partners LP dispuso de 1,500 acciones comunes: - 100 acciones a 60 d贸lares por acci贸n - 1,400 acciones a 70 d贸lares por acci贸n
  • Spearhead Insurance Solutions IDF LLC dispuso de 200 acciones a 70 d贸lares por acci贸n
  • Se ejercieron opciones put relacionadas con las disposiciones de acciones: - Una opci贸n put con precio de ejercicio de 60 d贸lares para 100 acciones - Diecis茅is opciones put con precio de ejercicio de 70 d贸lares para un total de 1,600 acciones

Tras estas transacciones, ADAR1 Partners LP mantiene la propiedad beneficiaria de 4,391,237 acciones, mientras que Spearhead Insurance Solutions posee 743,358 acciones. Todas las personas que reportan se consideran propietarios del 10% de Keros Therapeutics, con Daniel Schneeberger como administrador de las entidades relacionadas.

ADAR1 Capital Management LLC 氚� 甏�霠� 氩曥澑霌れ潃 2025雲� 6鞗� 20鞚� Keros Therapeutics(KROS) 歃濌秾鞐� 雽�頃� 欷戩殧頃� 瓯半灅 頇滊彊鞚� 氤搓碃頄堨姷雼堧嫟. 瓯半灅電� 歆侅爲 欤检嫕 毵る弰鞕� 頀嬱樀靺� 頄夓偓 氇憪毳� 韽暔頄堨姷雼堧嫟:

  • ADAR1 Partners LP電� 1,500欤�鞚� 氤错喌欤茧ゼ 觳橂秳頄堨姷雼堧嫟: - 欤茧嫻 60雼煬鞐� 100欤� - 欤茧嫻 70雼煬鞐� 1,400欤�
  • Spearhead Insurance Solutions IDF LLC電� 欤茧嫻 70雼煬鞐� 200欤�毳� 觳橂秳頄堨姷雼堧嫟
  • 欤检嫕 觳橂秳瓿� 甏�霠悳 頀嬱樀靺橃澊 頄夓偓霅橃棃鞀惦媹雼�: - 60雼煬 頄夓偓臧�鞚� 頀嬱樀靺� 1瓯�, 100欤� - 70雼煬 頄夓偓臧�鞚� 頀嬱樀靺� 16瓯�, 齑� 1,600欤�

鞚� 瓯半灅 鞚错泟 ADAR1 Partners LP電� 4,391,237欤�鞚� 鞁れ 靻岇湢甓岇潉 鞙犾頃橂┌, Spearhead Insurance Solutions電� 743,358欤�毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 氇摖 氤搓碃鞛愲姅 Keros Therapeutics鞚� 10% 靻岇湢鞛愲 臧勳＜霅橂┌, Daniel Schneeberger臧� 甏�霠� 氩曥澑鞚� 甏�毽瀽 鞐暊鞚� 毵￡碃 鞛堨姷雼堧嫟.

ADAR1 Capital Management LLC et les entit茅s associ茅es ont d茅clar茅 une activit茅 de trading importante sur les titres de Keros Therapeutics (KROS) le 20 juin 2025. Les transactions ont impliqu茅 脿 la fois des ventes directes d'actions ordinaires et l'exercice d'options de vente (put) :

  • ADAR1 Partners LP a c茅d茅 1 500 actions ordinaires : - 100 actions 脿 60 dollars chacune - 1 400 actions 脿 70 dollars chacune
  • Spearhead Insurance Solutions IDF LLC a c茅d茅 200 actions 脿 70 dollars chacune
  • Des options de vente li茅es ont 茅t茅 exerc茅es, correspondant aux cessions d'actions : - Une option put avec un prix d'exercice de 60 dollars pour 100 actions - Seize options put avec un prix d'exercice de 70 dollars pour un total de 1 600 actions

脌 la suite de ces transactions, ADAR1 Partners LP conserve la propri茅t茅 b茅n茅ficiaire de 4 391 237 actions, tandis que Spearhead Insurance Solutions d茅tient 743 358 actions. Toutes les personnes d茅clarantes sont consid茅r茅es comme propri茅taires de 10 % de Keros Therapeutics, Daniel Schneeberger 茅tant le gestionnaire des entit茅s associ茅es.

ADAR1 Capital Management LLC und verbundene Unternehmen meldeten am 20. Juni 2025 bedeutende Handelsaktivit盲ten mit Wertpapieren von Keros Therapeutics (KROS). Die Transaktionen umfassten sowohl direkte Aktienverk盲ufe als auch die Aus眉bung von Put-Optionen:

  • ADAR1 Partners LP ver盲u脽erte 1.500 Stammaktien: - 100 Aktien zu je 60 USD - 1.400 Aktien zu je 70 USD
  • Spearhead Insurance Solutions IDF LLC ver盲u脽erte 200 Aktien zu 70 USD pro Aktie
  • Zugeh枚rige Put-Optionen wurden ausge眉bt, entsprechend den Aktienver盲u脽erungen: - Eine Put-Option mit Aus眉bungspreis 60 USD f眉r 100 Aktien - Sechzehn Put-Optionen mit Aus眉bungspreis 70 USD f眉r insgesamt 1.600 Aktien

Nach diesen Transaktionen h盲lt ADAR1 Partners LP weiterhin den wirtschaftlichen Eigentum an 4.391.237 Aktien, w盲hrend Spearhead Insurance Solutions 743.358 Aktien besitzt. Alle meldenden Personen gelten als 10%-Eigent眉mer von Keros Therapeutics, wobei Daniel Schneeberger als Manager der verbundenen Unternehmen fungiert.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ADAR1 Capital Management, LLC
(Last) (First) (Middle)
3503 WILD CHERRY DRIVE, BUILDING 9
(Street)
AUSTIN TX 78738
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 X 100 D $60 4,392,637 I By ADAR1 Partners, LP(1)(2)
Common Stock 06/20/2025 X 1,400 D $70 4,391,237 I By ADAR1 Partners, LP(1)(2)
Common Stock 06/20/2025 X 200 D $70 743,358 I By Spearhead Insurance Solutions IDF, LLC(1)(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Put Option (right to sell) $60 06/20/2025 X 1 10/02/2024 06/20/2025 Common Stock 100 $0 0 I By ADAR1 Partners, LP(1)(2)
Put Option (right to sell) $70 06/20/2025 X 14 10/01/2024 06/20/2025 Common Stock 1,400 $0 0 I By ADAR1 Partners, LP(1)(2)
Put Option (right to sell) $70 06/20/2025 X 2 10/01/2024 06/20/2025 Common Stock 200 $0 0 I By Spearhead Insurance Solutions IDF, LLC(1)(2)
1. Name and Address of Reporting Person*
ADAR1 Capital Management, LLC
(Last) (First) (Middle)
3503 WILD CHERRY DRIVE, BUILDING 9
(Street)
AUSTIN TX 78738
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
ADAR1 Partners, LP
(Last) (First) (Middle)
3503 WILD CHERRY DRIVE, BUILDING 9
(Street)
AUSTIN TX 78738
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
ADAR1 Capital Management GP, LLC
(Last) (First) (Middle)
3503 WILD CHERRY DRIVE, BUILDING 9
(Street)
AUSTIN TX 78738
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
Schneeberger Daniel
(Last) (First) (Middle)
3503 WILD CHERRY DRIVE, BUILDING 9
(Street)
AUSTIN TX 78738
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
2. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
ADAR1 Capital Management, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger 06/24/2025
ADAR1 Partners, LP By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger 06/24/2025
ADAR1 Capital Management GP, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger 06/24/2025
Daniel Schneeberger, Manager /s/ Daniel Schneeberger 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider trading activity occurred at KROS on June 20, 2025?

On June 20, 2025, ADAR1 Partners, LP disposed of 1,500 shares of KROS common stock (100 shares at $60 and 1,400 shares at $70), while Spearhead Insurance Solutions IDF, LLC disposed of 200 shares at $70. These transactions were related to put option exercises.

How many shares does ADAR1 Partners own of KROS after the June 2025 transactions?

Following the reported transactions, ADAR1 Partners, LP beneficially owns 4,391,237 shares of KROS common stock indirectly, after disposing of 1,500 shares through put option exercises.

What put options were exercised in KROS stock by ADAR1 Partners?

ADAR1 Partners exercised put options for KROS stock on June 20, 2025, including 1 contract (100 shares) with a strike price of $60 and 14 contracts (1,400 shares) with a strike price of $70. All put options had an expiration date of June 20, 2025.

Who is Daniel Schneeberger's role in relation to KROS stock ownership?

Daniel Schneeberger serves as the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC. Through these positions, he may be deemed to indirectly beneficially own securities held by both ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.

What is ADAR1 Capital Management's relationship to KROS?

ADAR1 Capital Management, LLC is a 10% owner of KROS and serves as the investment manager of ADAR1 Partners, LP and sub-advisor of Spearhead Insurance Solutions IDF, LLC, allowing them to indirectly beneficially own securities held by both entities.
Stock KROS logo
Keros Therapeutics, Inc.

NASDAQ:KROS

KROS Rankings

#4229 Ranked by Market Cap
N/A Ranked by Dividends

KROS Latest News

Aug 6, 2025
Keros to Exclusively Prioritize the Clinical Advancement of KER-065
Aug 6, 2025
Keros Therapeutics Reports Second Quarter 2025 Financial Results
Jul 17, 2025
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Jun 9, 2025
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
Jun 9, 2025
Keros Announces Return of $375 Million in Excess Capital to Stockholders

KROS Latest SEC Filings

Aug 6, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Aug 6, 2025
[10-Q] Keros Therapeutics, Inc. Quarterly Earnings Report
Aug 6, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Jul 17, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event
Jul 15, 2025
[8-K] Keros Therapeutics, Inc. Reports Material Event

KROS Stock Data

585.27M
38.64M
2.31%
110.12%
12.43%
Biotechnology
Pharmaceutical Preparations
United States
LEXINGTON